Anpario is pleased to announce continued progress in expanding its product portfolio, marked by the successful global rollout of two new solutions that are already generating strong early momentum.
The first, AmpLIPhy, is an innovative natural emulsifier designed to improve fat digestion, representing a key advancement in Anpario’s internal product development pipeline. The second, QuadriCal a calcium supplement bolus, produced in Barneveld by BioVet an Anpario company strengthening the Group’s ruminant offering.
Both products have already achieved registrations in several key markets, with additional regulatory approvals expected in the near term. This progress supports accelerated commercialisation and reinforces Anpario’s ability to bring novel, high-quality solutions to market efficiently.
The global rollout of QuadriCal marks an important milestone in expanding Anpario’s ruminant portfolio, particularly across high-growth regions including the Middle East & Africa (MEA), Asia, and the Americas. The launch demonstrates the strength of collaboration across the organisation, with teams in Manton Wood and Barneveld working closely to ensure market readiness and successful deployment.
Importantly, the expansion of QuadriCal beyond the United States delivers against the strategic objective of leveraging Anpario’s global infrastructure to extend the reach of the BioVet product range. As part of this integration, BioVet will transition to the Anpario brand in October 2026, further strengthening the Group’s unified global presence.
AmpLIPhy highlights Anpario’s capability for agile, innovation-led product development. With applications across multiple regions including Asia, MEA, LATAM, and the EU, the product is well-positioned to scale rapidly through existing sales channels and strong customer relationships. Early sales in MEA provide a solid foundation for further growth, particularly within the monogastric sector.
These developments underline Anpario’s commitment to innovation, operational excellence, and global market expansion. The Company expects both products to contribute meaningfully to future growth as adoption increases and additional regulatory milestones are achieved.